Capital International Investors
ALNY icon

Capital International Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital International Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-550
Closed -$246K – 457
2025
Q3 		$246K Buy
+550
New +$224K ﹤0.01% 445
2025
Q1 		– Sell
-1,418,602
Closed -$334M – 443
2024
Q4 		$334M Sell
1,418,602
-2,552,261
-64% -$671M 0.06% 190
2024
Q3 		$1.09B Buy
3,970,863
+79,804
+2% +$20.8M 0.21% 107
2024
Q2 		$946M Buy
3,891,059
+239,842
+7% +$37.9M 0.19% 109
2024
Q1 		$546M Buy
3,651,217
+64,560
+2% +$10.8M 0.11% 156
2023
Q4 		$687M Buy
3,586,657
+488,814
+16% +$83.3M 0.15% 132
2023
Q3 		$549M Buy
3,097,843
+217,200
+8% +$41.4M 0.14% 147
2023
Q2 		$547M Buy
2,880,643
+651,054
+29% +$129M 0.13% 158
2023
Q1 		$447M Buy
2,229,589
+223,968
+11% +$47.1M 0.11% 168
2022
Q4 		$477M Buy
2,005,621
+58,907
+3% +$12.6M 0.13% 164
2022
Q3 		$390M Buy
1,946,714
+312,477
+19% +$59.6M 0.11% 174
2022
Q2 		$238M Buy
+1,634,237
New +$232M 0.06% 229

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors's ALNY Position: Q4 2025 in Review

Capital International Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 550 shares — an estimated $246K sold.

Capital International Investors first reported a position in ALNY in Q2 2022 and held it in 12 quarters. The position peaked at $1.09B in Q3 2024. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Capital International Investors reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capital International Investors sold 550 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $246K.
  • Capital International Investors first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 12 quarters.
  • Capital International Investors's Alnylam Pharmaceuticals position peaked at $1.09B in Q3 2024.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Capital International Investors's 13F filing for Q4 2025, filed 11 Feb 2026.